All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On March 29, 2021, it was announced that the phase II GMED16-001 trial, evaluating an intravenous formulation of arsenic trioxide in patients with chronic graft-versus-host disease (cGvHD), met its primary endpoint.
This prospective, multicenter, non-randomized study evaluated the clinical efficacy of arsenic trioxide (a new selective immunosuppressive/anti-inflammatory drug for cGvHD) administered intravenously as first-line treatment in 21 patients with moderate to severe cGvHD. The primary endpoint of the study was to show an improvement in complete or partial remission rates at 6 months.
Patients received daily intravenous infusions of arsenic trioxide over a 4-week period, in combination with prednisone with or without cyclosporine. The use of arsenic trioxide led to a drastic reduction of the prednisone dose, starting at Week 6. Discontinuation of prednisone was planned once patients achieved a complete remission.
After the 6-month follow-up, the primary efficacy endpoint was met, with a 75% overall response rate. Sustained response was also observed at 12 months post-treatment in all patients.
Based on these promising results, arsenic trioxide is expected to advance into a phase III trial to confirm its efficacy.
Subscribe to get the best content related to GvHD delivered to your inbox